CELLforCURE by SEQENS
Is this your company? Claim this profile
Advanced Modalities
Drug Product
Analytical & Bioanalytical Services
Regulatory, Tech Transfer & Support Services
Company Overview
About
CELLforCURE by SEQENS is a pharmaceutical CDMO offering comprehensive services.
Key Expertise
Specialized in Gene Therapy, Cell Therapy, mRNA
Therapeutic Areas
Neurology
Quick Facts
HQ:France
Founded:2012
Employees:1,703
Capabilities & Services
Core Capabilities
- Cytotoxic / ADC Handling
- High-Potency API
- Sterile Fill/Finish
Types of Organization
GMP Manufacturing
Quality Systems
Regulatory Support
Dosage Forms
Topical / Transdermal
Containment Capabilities
OEB 5 (≤1 µg/m³)
Cytotoxic / ADC Handling
Production Scales
Pilot Scale
Clinical
Commercial Scale
Markets Served
Asia-Pacific
Regulatory Approvals
Drug Approval FB8ZM4
EMA · #APR-KNDEIZHR · 2021-02-01
Certifications
EMA GMP Certificate
European Medicines Agency
Cert #: CERT-H2CS5ZHS
Issued: 2020-05-01
Expires: 2025-01-13
ISO 9001:2015
International Organization for Standardization
Cert #: CERT-7PQD02K0
Issued: 2020-11-13
Expires: 2025-03-06
WHO GMP
World Health Organization
Cert #: CERT-LOU9M254
Issued: 2020-05-27
Expires: 2025-04-16
Health Canada GMP
Health Canada
Cert #: CERT-R367ADB1
Issued: 2020-11-07
Expires: 2025-08-27
Loading CDMO intelligence...
Key facts about CELLforCURE by SEQENS
- CELLforCURE by SEQENS is headquartered in France.
- CELLforCURE by SEQENS was founded in 2012.
- CELLforCURE by SEQENS has 1,703 employees.
- CELLforCURE by SEQENS's capabilities include Cytotoxic / ADC Handling, High-Potency API and Sterile Fill/Finish.
Find CDMOs like CELLforCURE by SEQENS
Directory pages this company appears in, each with the full list of matching manufacturers.